ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

May 04, 2007 16:45 ET

ALDA Grants Incentive Stock Options

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 4, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has granted incentive stock options to certain directors and employees to purchase an aggregate of 1,150,000 common shares at an exercise price of $0.12 and a term of two years, expiring on May 3, 2009. The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 15, 2006 and subsequently accepted by the Exchange. The total number of options outstanding after this grant will be 2,380,000.

About ALDA Pharmaceuticals Corp.

ALDA's patent-pending T36® therapeutic products contain active ingredients in very low concentrations that act in concert to disrupt the physical structure of all infectious organisms rather than interfering with their metabolic pathways. The competitive advantage is a high degree of effectiveness and safety while preventing microbial resistance, side effects or toxicity. The Company has identified global markets of $10 Billion in its targeted disease areas.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information